Ex Vivo Gene Therapy Clinical Trial for RDEB Using Genetically Corrected Autologous Skin Equivalent Grafts

NCTID	NCT04186650 (View at clinicaltrials.gov)
Description	This phase I/II clinical trial aims to treat 3 adult subjects with Recessive Dystrophic Epidermolysis Bullosa, expressing residual C7 levels, by genetically corrected autologous skin equivalent grafts on selected areas (up to 300 cm2). (Show More)
Indication	Dystrophic Epidermolysis Bullosa
Compound Name	EF1a-COL7A1-SIN retroviral vector transduced autologous skin
Sponsor	Institut National de la Santé Et de la Recherche Médicale, France
Funder Type	Other gov
Status	Active not recruiting
Enrollment Count	3

No.of Trial Sites	1
Locations	France

Has US IND	False
Recent Updates